MJP Associates’s CorMedix CRMD Stock Holding History

MJP Associates’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25,000	Closed	-$94K	–	233
2023 Q4	$94K	Buy	+25,000	New	+$86K	0.03%	176

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MJP Associates's CRMD Position: Q1 2024 in Review

MJP Associates sold out of CorMedix (CRMD) in Q1 2024, closing a stake of 25,000 shares — an estimated $94K sold.

MJP Associates first reported a position in CRMD in Q4 2023 and held it in 1 quarter. The position peaked at $94K in Q4 2023. 91 funds tracked by Wall St. Rank hold CRMD as of Q1 2024.

MJP Associates reported no remaining CorMedix position as of Q1 2024 after selling out during the quarter.
MJP Associates sold 25,000 CorMedix shares in Q1 2024, an estimated $94K.
MJP Associates first reported a position in CorMedix in Q4 2023 and held it in 1 quarter.
MJP Associates's CorMedix position peaked at $94K in Q4 2023.
91 funds tracked by Wall St. Rank held CorMedix as of Q1 2024.

Based on MJP Associates's 13F filing for Q1 2024, filed 11 Apr 2024.